Nexalis Therapeutics Ltd
NX1
Company Profile
Business description
Nexalis Therapeutics Ltd is an Australian clinical stage drug development company that is focused on developing therapies to address unmet medical needs in pain management and mental health sectors. Its pipeline includes three clinical drug candidates focused on treatment-resistant depression, breakthrough cancer pain, and panic disorder, each addressing areas of unmet medical need and potential commercial demand.
Contact
505 Little Collins Street
Level 9
MelbourneVIC3000
AUST: +61 390701221
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
Stocks News & Analysis
stocks
Tesla: Shares fall as deliveries come in below consensus
Long-term growth less reliant on auto sales.
stocks
Will Australia’s dwindling fuel supplies impact this share?
Australia’s petrol reserves have dropped from 60 to 35 days.
stocks
US tech stocks sank in Q1 - but the biggest opportunities may be ahead
These 12 undervalued technology stocks look attractive today.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,774.90 | 124.80 | -1.40% |
| CAC 40 | 7,962.39 | 0.00 | 0.00% |
| DAX 40 | 23,168.08 | 130.81 | -0.56% |
| Dow JONES (US) | 46,669.88 | 165.21 | 0.36% |
| FTSE 100 | 10,436.29 | 71.50 | 0.69% |
| HKSE | 25,116.53 | 177.50 | -0.70% |
| NASDAQ | 21,996.34 | 117.16 | 0.54% |
| Nikkei 225 | 53,413.68 | 290.19 | 0.55% |
| NZX 50 Index | 12,902.15 | 76.28 | 0.59% |
| S&P 500 | 6,611.83 | 29.14 | 0.44% |
| S&P/ASX 200 | 8,579.50 | 105.50 | -1.21% |
| SSE Composite Index | 3,919.29 | 29.27 | -0.74% |